PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email info@lamerie.com
Nipocalimab demonstrates sustained disease control in …
1 天前 · First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied . SAVANNAH, GA, USA I October 15, 2024 I Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChR a positive adolescents (aged 12 ...
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® …
1 天前 · THOUSAND OAKS, CA, USA I October 15, 2024 I Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA ® (inebilizumab-cdon) for the treatment of adults with generalized myasthenia gravis (gMG), a rare ...
All news - Pipelinereview
6 天之前 · PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email info@lamerie.com
Beacon Therapeutics Announces Positive 24-Month Data from …
1 天前 · LONDON, UK and CAMBRIDGE, MA, USA I October 15, 2024 I Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading ophthalmic gene therapy company with a purpose to save and restore the vision of patients with blinding retinal diseases, today announced the ...
GSK announces positive phase III results from ANCHOR trials for ...
1 天前 · LONDON, UK I October 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with CRSwNP. Both trials met their co-primary endpoints of a ...
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of …
1 天前 · CAMBRIDGE, MA, USA & MONTREAL, Canada I October 14, 2024 I Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s Phase 1 (POLAR) clinical trial evaluating RP-3467, a Polθ ATPase inhibitor, alone and in combination with the poly-ADP ribose polymerase ...
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) …
2024年9月16日 · Longest survival follow-up ever reported for a Phase III immunotherapy trial in this setting. WILMINGTON, DE, USA I September 16, 2024 I Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) plus IMJUDO ® (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at five years for patients with unresectable ...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE
2024年8月21日 · RYBREVANT ® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib. Following Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT ® plus LAZCLUZE™ reduced the risk of disease progression or death by 30 percent versus osimertinib, with a nine-month-longer median duration of response
Patritumab Deruxtecan Granted Priority Review in the U
2023年12月22日 · Submission based on HERTHENA-Lung01 results showing patritumab deruxtecan demonstrated clinically meaningful and durable responses in patients with advanced EGFR-mutated non-small cell lung cancer previously treated with two or more systemic therapies